DavidCPortnoyMD
Oncology • Germantown, TNAssistant Professor, Medicine-Hematology, University of Tennessee Health Science Center College of Medicine
Dr. Portnoy is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
7945 Wolf River Blvd
Germantown, TN 38138Phone+1 901-683-0055Fax+1 901-685-9718
Education & Training
Beth Israel Deaconess Medical CenterFellowship, Hematology and Medical Oncology, 2006 - 2009
University of Pennsylvania Health SystemResidency, Internal Medicine, 2003 - 2006
SUNY Upstate Medical UniversityClass of 2003
Certifications & Licensure
MS State Medical License 2009 - 2025
TN State Medical License 2009 - 2025
MA State Medical License 2006 - 2010
PA State Medical License 2003 - 2006- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Patient-Centered Specialty Practice Recognition Program National Committee for Quality Assurance, 2014-2017
Clinical Trials
- Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line to Treat Biliary Cancer Start of enrollment: 2013 Apr 01
- A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma Start of enrollment: 2015 Sep 14
Publications & Presentations
PubMed
- 53 citationsSubgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patient...Radka Obermannova, E. Van Cutsem, Takayuki Yoshino, G. Bodoky, Jana Prausová
Annals of Oncology. 2016-11-01 - 77 citationsAnalysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III st...Josep Tabernero, Rebecca R. Hozak, Takayuki Yoshino, Allen Lee Cohn, Radka Obermannova
Annals of Oncology. 2017-09-01 - 597 citationsRamucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy ...Josep Tabernero, Takayuki Yoshino, Allen Lee Cohn, Radka Obermannova, György Bodoky
The Lancet. Oncology. 2015-05-01
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
